The Oncotype DX test can predict the aggressiveness of your cancer, helping you decide which treatment is right for you.
The information presented on this site is intended to provide patients with newly diagnosed prostate cancer, as well as their friends and family, an opportunity to learn how the information provided by the Oncotype DX Genomic Prostate Score can be used, along with other clinical measures, to help patients and their doctors make treatment decisions. Patients should consult their doctor to determine the best treatment decision for their individual disease.
National Comprehensive Cancer Network (NCCN) and NCCN are registered trademarks of NCCN. NCCN does not endorse any product or therapy.
Copyright © 2013-2014 Genomic Health, Inc. All rights reserved. Genomic Health, Oncotype, and Oncotype DX are trademarks of Genomic Health Inc. MyProstateCancerTreatment.org is sponsored by Genomic Health, Inc., a clinical laboratory in Redwood City, California that developed and offers the Oncotype DX Prostate Cancer Assay. Genomic Health is responsible for the content of MyProstateCancerTreatment.org.